Slide 1: Arctic Bioscience Q4 2025 update / prelim. FY 2025 results
Arctic Bioscience Presentation of financial results; Q4 2025 update / prelim. FY 2025 results February 26th 2026 Christer L. Valderhaug (CEO) Runhild Gammelsæter (Medical Director) Jone R. Slinning (CFO) 1
Slide 2: Disclaimer
Disclaimer Matters discussed in this correct, and their methodology ascertain from the information Presentation may constitute or may be forward-looking and published by that third party, no include forward-looking speculative. facts have been omitted that statements. Forward-looking would render th
Slide 3: Developing and commercializing pharmaceutical and nutraceutical products
Developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds, utilizing proprietary technology and methodology
Slide 4: Agenda
Agenda Operational highlights Operational review Nutra 2025 consolidated Group financial review (prelim.) Operational review Pharma Business outlook Q&A
Slide 5: Intro and 2025 operational highlights
Intro and 2025 operational highlights 5
Slide 6: 2025 highlights
2025 highlights HRO350 significantly reduced systemic inflammation in the HeROPA trial SII post-hoc analyses on all patients in per-protocol population ROMEGA® Singapore Nutra boost end of year Nutra order intake strong ROMEGA® Premium and Skin Refine Strong ending to the year with quarterly Solid o
Slide 7: Operational review Nutra
Operational review Nutra 7
Slide 8: B2C sales
B2C sales B2C sales of ROMEGA® products in Norway is at level with same period last year, though with significantly less marketing spending – mainly subscription based sales Offline sales trough Sunkost, Life, Kinsarvik and Farmasiet in Norway is slightly lower than last year – but more profitable B
Slide 9: Nutra B2B
Nutra B2B B2B products: sold in Americas, Europe and APAC − Bulk products (oil, capsules, protein) − Private label − Customized products − The ROMEGA® ingredient present in more than 40 consumer brands globally Americas developing well and expected to grow further – opened a new large account in Q4-
Slide 10: ROMEGA® in China
ROMEGA® in China ROMEGA® products are currently sold cross-border eCommerce into China from Hong Kong Despite a challenging consumer market in China this year with high degree of uncertainty and reduced consumer spending – our partner has managed so keep sales revenues at level with last year Our be
Slide 11: Arctic Algae - Development of oral vaccines for aquaculture
Arctic Algae - Development of oral vaccines for aquaculture • Current vaccination methods (injection & immersion) are stressful for fish, labor-intensive, costly, and hard to apply • Oral vaccines provide a simple, scalable, and stress-free alternative as a booster vaccine • Microalgae act as safe,
Slide 12: 2025 consolidated group financial review (prelim.)
2025 consolidated group financial review (prelim.) 12
Slide 13: Key financial figures
Key financial figures SALES REVENUES GROSS MARGIN AVAILABLE LIQUIDITY 43,5 29,0% 109,6 27,3% 27,1% 39,8 33,8 7,0 5,2 2023 2024 2025 2023 2024 2025 31.12.2023 31.12.2024 31.12.2025
Slide 14: Breakdown of Nutra revenue
Breakdown of Nutra revenue REVENUE BY BUSINESS LINE REVENUE BY REGION 50 000 50 000 45 000 45 000 40 000 40 000 29 % 20 % 35 000 35 000 30 000 30 000 13 % 25 000 89 % 25 000 33 % 88 % 20 000 20 000 15 000 15 000 43 % 29 % 10 000 10 000 5 000 5 000 11 % 12 % 16 % 18 % - - 2024 2025 2024 2025 B2C B2B
Slide 15: EBITDA results
EBITDA results 2025 nutra revenues slightly down compared to last year, significantly TNOK 2025 2024 affected by recall issue which arose late 2024 with impacts on deliveries in 2025 Total revenues 42 622 44 404 • Strong development in the American market with a 143 % annual Sales revenue 39 846 43
Slide 16: Cash flow development
Cash flow development TNOK 2025 2024 Available liquidity end of period NOK 5,2 million Net cash flow from operating activities -22 679 -45 357 Cash flow from operations NOK -22,7 million, mainly driven by negative operating result Net cash flow from investment activities -22 671 -50 629 Net cash flo
Slide 17: Operational review Pharma
Operational review Pharma 17
Slide 18: Pharmaceutical pipeline: Status
Pharmaceutical pipeline: Status ABS302 HRO350 HCO Brain development in Mild to moderate Psoriasis Glaucoma extremely premature infants Status Status Status • Phase 2b study completed in 2025 and • Successful formulation of two liquid • Successful clinical pilot study conducted data analysis complete
Slide 19: HRO350: Psoriasis is an inflammatory disease
HRO350: Psoriasis is an inflammatory disease Novel oral product meets an unmet medical need for patients with non-severe psoriasis Comments Psoriasis is an inflammatory skin disease, associated with comborbid disorders Disease severity – how extensive or serious the skin involvement is – often goes
Slide 20: HRO350: Significant reduction of systemic inflammation in two clinical trials
HRO350: Significant reduction of systemic inflammation in two clinical trials Consistent reduction in SII across two clinical trials in patients with mild-to-moderate psoriasis HeROPA study 2023-2025 Haukeland study 2018-2019 25% reduction in inflammation (SII25) 25% reduction in inflammation (SII25
Slide 21: Significant improvements on skin symptoms, inflammation and quality of life
Significant improvements on skin symptoms, inflammation and quality of life in patients with mild-to-moderate inflammation (SII ≦ 506) at baseline PGA 0/1 (SII ≦ 506) 25% improvement in SII (SII ≦ 506) DLQI 0/1(SII ≦ 506) Comments “Clear-or-almost clear skin” Reduction in inflammation ”No effect on
Slide 22: HCO: Potential in enabling neuroprotection in glaucoma
HCO: Potential in enabling neuroprotection in glaucoma Pilot study confirms potential of Herring Caviar Oil in Primary Open-Angle Glaucoma Anti-inflammatory with neuroprotective potential • Neuroprotective effects on RGC by DHA and derivatives • Benefits in neurodegenerative disorders of omega-3 HCO
Slide 23: Pharmaceutical pipeline: Outlook
Pharmaceutical pipeline: Outlook ABS302 HRO350 HCO Brain development in Mild to moderate Psoriasis Glaucoma extremely premature infants Next steps Next steps Next steps • Partner search (funding phase 3) • Produce material and conduct • Partner search • Publish results/articles preclinical • Specifi
Slide 24: Business outlook
Business outlook 24
Slide 25: Outlook 2026
Outlook 2026 HeROPA development Liquidity situation closely Nutra potential monitored Strategic opportunities for further Positive dialogue with Group’s Increased nutraceutical development and regulatory bank. The Board continuously revenues expected in 2026 engagement will be evaluated assessing me
Slide 26: Arctic Bioscience
ARCTIC Bioscience
Slide 27: Contact
Contact CEO - Christer L. Valderhaug: christer@arctic-bioscience.com CFO - Jone R. Slinning jone@arctic-bioscience.com Medical Director - Runhild Gammelsæter: runhild@arctic-bioscience.com Subscribe to news www.arctic-bioscience.com/investors/home